Drug Topics June 11, 2024
Killian Meara

The Lingo and Libre Rio from Abbott are based on the company’s FreeStyle Libre sensing technology.

The FDA has provided clearance to 2 over-the-counter (OTC) continuous glucose monitor (CGM) systems, health care technology company Abbott announced in a release.1 The new OTC devices are based on the company’s FreeStyle Libre sensing technology, which is the most widely used CGM system in the world.

The Lingo and Libre Rio were both designed to meet different consumer needs. The Lingo aims to help adults gain a better understanding of their health and improve wellness, while the Libre Rio is for adults with type 2 diabetes (T2D) who do not use insulin and typically manage their disease through lifestyle modifications. The approval for...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Digital Health, FDA, Govt Agencies, Medical Devices, Technology, Wearables
Related Articles:
FDA says the Zepbound shortage is over. Here’s what that means for compounding pharmacies, patients who used off-brand versions
Gene Therapy Shows Long-Term Vision Benefits in Rare Eye Disease
Trump's Picks for Top Health Jobs Not Just Team of Rivals but 'Team of Opponents'
FDA updates definition of 'healthy'
FDA approves Eli Lilly's weight loss drug Zepbound for sleep apnea, expanding use in U.S.

Share This Article